Collegium Pharmaceutical, Inc. (COLL) Stock

Collegium Pharmaceutical, Inc. (COLL) is a Healthcare stock trading at $33.51 (as of 2026-06-18), with a market capitalization of $1.09B and a trailing P/E of 16.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Collegium Pharmaceutical, Inc. develops and commercializes specialty medicines for pain management, including Xtampza ER, Nucynta ER, and Nucynta IR formulations. Its products are used for pain severe enough to require treatment that may be long-term and around-the-clock.

Valuation — source: SEC EDGAR (first-party)
Price	$33.51
Market Cap	$1.09B
P/E Ratio	16.8
EV / EBITDA	4.3
Price / Book	3.60
Price / Sales	1.41
DCF Value (model)	$216.31
DCF Upside vs Price	545.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$780.57M
Net Margin	8.1%
Return on Equity	24.0%
Current Ratio	1.71
Revenue Growth (YoY)	23.6%
EPS Growth (YoY)	-7.5%
FCF Growth (YoY)	61.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	1.40 (distress)

Valuation vs Sector & Industry
Stock P/E	16.8
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-19.8%
vs Industry	-2.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($169.78M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Vikram Karnani
Employees	357
Country	US
IPO Date	2015-05-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.